Nextage Therapeutics Ltd (NXTG) - Net Assets
Based on the latest financial reports, Nextage Therapeutics Ltd (NXTG) has net assets worth ILA-5.54 Million ILA (≈ $-14.84K USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA353.00K ≈ $946.38 USD) and total liabilities (ILA5.89 Million ≈ $15.79K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Nextage Therapeutics Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA-5.54 Million |
| % of Total Assets | -1568.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -481.79% |
| 10-Year Change | N/A |
| Growth Volatility | 51.34 |
Nextage Therapeutics Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Nextage Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore NXTG asset base for the complete picture of this company's asset base.
Annual Net Assets for Nextage Therapeutics Ltd (2017–2024)
The table below shows the annual net assets of Nextage Therapeutics Ltd from 2017 to 2024. For live valuation and market cap data, see NXTG stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA-5.54 Million ≈ $-14.84K |
-102.27% |
| 2023-12-31 | ILA-2.74 Million ≈ $-7.34K |
-542.49% |
| 2022-12-31 | ILA-426.00K ≈ $-1.14K |
-182.56% |
| 2021-12-31 | ILA516.00K ≈ $1.38K |
-64.41% |
| 2020-12-31 | ILA1.45 Million ≈ $3.89K |
-60.34% |
| 2019-12-31 | ILA3.66 Million ≈ $9.80K |
+321.71% |
| 2018-12-31 | ILA-1.65 Million ≈ $-4.42K |
-137.16% |
| 2017-12-31 | ILA4.44 Million ≈ $11.90K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nextage Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6893700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA37.02 Million | % |
| Total Equity | ILA-5.52 Million | 100.00% |
Nextage Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Nextage Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Witbe Net SA
PA:ALWIT
|
$5.79 Million |
|
FIREFOX GOLD CORP.
F:FIY
|
$5.80 Million |
|
Teuza A Fairchild Technology Venture Ltd
TA:TUZA
|
$5.80 Million |
|
Hensel Davest Indonesia Tbk PT
JK:HDIT
|
$5.81 Million |
|
Elecster Oyj A
HE:ELEAV
|
$5.79 Million |
|
Till Capital Ltd
V:TIL
|
$5.77 Million |
|
North Atlantic Smaller Companies Investment Trust PLC
LSE:NAS
|
$5.77 Million |
|
Sanwil Holding SA
WAR:SNW
|
$5.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nextage Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,900,000 to -5,517,000, a change of -2,617,000.
- Net loss of 3,283,000 reduced equity.
- New share issuances of 639,000 increased equity.
- Other factors increased equity by 27,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-3.28 Million | -59.51% |
| Share Issuances | ILA639.00K | +11.58% |
| Other Changes | ILA27.00K | +0.49% |
| Total Change | ILA- | % |
Book Value vs Market Value Analysis
This analysis compares Nextage Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ILA-1.43 | ILA64.10 | x |
| 2019-12-31 | ILA1.63 | ILA64.10 | x |
| 2020-12-31 | ILA0.06 | ILA64.10 | x |
| 2021-12-31 | ILA-0.01 | ILA64.10 | x |
| 2022-12-31 | ILA-0.03 | ILA64.10 | x |
| 2023-12-31 | ILA-0.10 | ILA64.10 | x |
| 2024-12-31 | ILA-0.16 | ILA64.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nextage Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -794.92%
- • Asset Turnover: 1.17x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-160.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -128.78% | -1415.31% | 0.03x | 2.78x | ILA-6.18 Million |
| 2018 | 0.00% | -2280.68% | 0.07x | 0.00x | ILA-8.57 Million |
| 2019 | -56.40% | -703.03% | 0.05x | 1.62x | ILA-2.46 Million |
| 2020 | -1101.10% | -8359.16% | 0.05x | 2.81x | ILA-16.11 Million |
| 2021 | 0.00% | -8492.31% | 0.02x | 0.00x | ILA-7.70 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-5.50 Million |
| 2023 | 0.00% | -442.81% | 0.80x | 0.00x | ILA-3.59 Million |
| 2024 | 0.00% | -794.92% | 1.17x | 0.00x | ILA-2.73 Million |
Industry Comparison
This section compares Nextage Therapeutics Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,915,843,221
- Average return on equity (ROE) among peers: 18.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nextage Therapeutics Ltd (NXTG) | ILA-5.54 Million | -128.78% | N/A | $5.79 Million |
| Canzon Israel Ltd (CNZN) | $7.46 Million | -32.77% | 0.24x | $1.81 Million |
| Intercure (INCR) | $3.92 Million | -168.61% | 0.57x | $37.38 Million |
| Intelicanna Ltd (INTL) | $8.07 Billion | 15.95% | 6.02x | $8.85 Million |
| Kamada (KMDA) | $89.97 Million | 0.49% | 0.55x | $372.69 Million |
| Rekah Pharmaceutical Industry Ltd (REKA) | $161.98 Million | 3.83% | 1.76x | $34.21 Million |
| Seach Medical Group Ltd (SEMG) | $79.25 Million | 15.10% | 0.17x | $19.06 Million |
| Teva Pharmaceutical Industries Ltd (TEVA) | $8.69 Billion | -27.07% | 4.06x | $1.09 Billion |
| Together Startup Network Ltd (TGTR) | $549.00K | 387.98% | 0.54x | $9.61 Million |
| Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) | $136.06 Million | -24.21% | 0.43x | $28.21 Million |
About Nextage Therapeutics Ltd
Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.